Rhofade Savings Card now available

April 25, 2017
 Allergan has announced the availability of the Rhofade Cream Savings Program, which is promoted as allowing access to a prescription of Rhofade for as little as $35. This out-of-pocket amount only applies if you have commercial insurance that covers Rhofade. If your insurance does not cover Rhofade `you may pay as little as $75′.

The list of conditions and exclusions continues;

  • Valid for up to 4 fills of a valid prescription
  • Not valid if you are enrolled in Medicare, Medicaid or HMO reimburse
  • Valid until 31st December 2017

It is interesting to see Allergan launch a savings card to conincide with the release of Rhofade. This could be an attempt by the company to project the story that Rhofade is an affordable treatment. This story only has legs if you have health insurance coverage of course, without coverage a tube of Rhofade cream will be unaffordable by most.

Rhofade without medical insurace

If you do not have medical insurance, Rhofade will be an expensive option. Please leave us a comment below if you have been quoted a full retail price for a tube of Rhofade. Your fellow rosacea sufferers will be greatful to discover how much Rosacea Prescriptions Really Cost. Also please do leave us a comment with your Rhofade review when you can.

For full information on the Rhofade Cream Savings Program see the Rhofade web site.

Related Articles


Rhofade Reviews

April 11, 2017

Allergan’s Oxymetazoline based cream, Rhofade (oxymetazoline hydrochloride cream 1%) – for the treatment of the redness of rosacea is now generally available. Does Rhofade work for your red face? See Rhofade User Reviews for all the low down.

Difference between Rhofade and Mirvaso

January 26, 2017

RHOFADE is the first and only alpha1A adrenoceptor agonist approved for persistent facial erythema associated with rosacea in adults.

Mirvaso is  is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.

See Mirvaso and Rhofade for more information.

What is Rhofade?

January 26, 2017

Finally the oxymetazoline treatment from Allergan has been approved by the FDA and it is known as Rhofade.

Tinted ZincO Cream

June 8, 2016

It has been a long time coming, but here, finally I want collect some RosaceaCare Tinted ZincO Cream User Reviews where one of the best rosacea sunscreens can be discussed.

Honevo Kanuka Honey proven to help Rosacea Sufferers

April 3, 2015

Honevo Kanuka Honey proven to help Rosacea Sufferers

A poster session at the just completed 2015 AAD Meeting in San Francisco has published some results that show a special formulation of Kanuka Honey is able to benefit rosacea sufferers.

The information around this announcement tells us that a `large clinical trial has proved that Honevo, a medical grade kanuka honey formulation, developed by New Zealand company HoneyLab, is an effective and safe treatment rosacea.’

The clinical trial results demonstration that 65% of triallists showed an improvement in their rosacea – 34% had a large improvement and in “13% the disease disappeared completely”. Improvements were seen in within 2 weeks.


Rosacea News September 2014

October 14, 2014

Galderma offers physicians advice for Mirvaso Rebound Redness

1. Galderma offers physicians advice for Mirvaso Rebound Redness

Galderma have added a page to the Mirvaso web site to guide doctors dealing with the potential for “rebound” by users of Mirvaso. This would seem to confirm that Galderma is aware that there are users of MIRVASO who are experiencing adverse events. The use of double quotes around “rebound” and “worsening” is interesting and […]


New adverse allergic contact reaction to Mirvaso noted in JAAD

2. New adverse allergic contact reaction to Mirvaso noted in JAAD

The latest edition of the Journal of American Academy of Dermatology lists an exchange by letter detailing a contact dermatitis allergic reaction to Mirvaso. The adverse reaction was found by the doctors to be caused by the main active ingredient in Mirvaso, Brimonidine. The writers of the letter to the JAAD caution other doctors that […]


Laropiprant (MK-0524) fails as a treatment for a red face

3. Laropiprant (MK-0524) fails as a treatment for a red face

We don’t often get to see research results published that show a proposed new treatment doesn’t work. It make sense that researchers and pharmaceutical companies would rather see their research and development efforts succeed and lead only to new products. A clinical trial for MK-0524, Merck’s designation for their product known as Laropiprant, has confirmed […]



Ivermectin better than Metrogel 0.75% for papules and pustules

4. Ivermectin better than Metrogel 0.75% for papules and pustules

Some just published research from the Ivermectin Phase III study group suggests that Ivermectin 1% cream once a day is better than Metronidazole 0.75% twice a day at treating the papules and pustules of rosacea. The British Journal of Dermatology paper tells us that although both Ivermectin and Metronidazole did lead to a reduction in […]


Rossoseq gets some publicity from the Irish Examiner

5. Rossoseq gets some publicity from the Irish Examiner

Some friendly words from the Irish Examiner recently seeking to create an Irish link to the topical treatment known as Rossoseq. According to the article Rossoseq is being made available firstly in Ireland. Rossoseq has been associated with a mild reduction in redness in a small trial of 10 users. What is Rossoseq? The product […]



Mirvaso Gel is now available in Australia

6. Mirvaso Gel is now available in Australia

According to the Galderma AU web site, Mirvaso is now available in Australia. Here are the Australian versions of the MIRVASO Gel User Consumer Information and also Mirvaso Product Information. Mirvaso was first registered in the Australian Register of Therapeutic Goods on the 4th of August 2014. See the listing here – MIRVASO CMI Mirvaso […]